Only) until a shared care protocol or agreement is in place. Dulaglutide Amber Dulaglutide was agreed to be included onto the formulary (Trulicity) in February and listed as Amber only’. It ‘specialist have been discussed further and the decision has been made for Trulicity to remain Amber but to include the following phrase from the diabetes pathway ‘Initiation of GLP1 analogues to be carried out by only prescribers trained in insulin therapy’ this will enable prescribers sufficiently trained to prescribe it, and avoid unnecessary restrictions. 2)NICE Technical Appraisals March and April 2018 Technical Appraisals NICE TA indication RAG rating NICE TA504 Pirfenidone for treating idiopathic pulmonary fibrosis RED NICE Ixazomib with lenalidomide and dexamethasone for RED treating relapsed or refractory multiple myeloma. NICE : Sofosbuvir–velpatasvir–voxilaprevir for treating RED chronic hepatitis C. NICE Brodalumab for treating moderate to severe plaque RED psoriasis NICE Tivozanib for treating advanced renal cell carcinoma RED NICE Pertuzumab with trastuzumab and docetaxel for RED treating HER2-positive breast cancer. NICE Daratumumab monotherapy for treating relapsed and RED refractory multiple myeloma.
Only) until a shared care protocol or agreement is in place. Dulaglutide (Trulicity) Amber Dulaglutide was agreed to be included onto the formulary in February and listed as Amber ‘specialist only’. It have been discussed further and the decision has been made for Trulicity to remain Amber but to include the following phrase from the diabetes pathway ‘Initiation of GLP1 analogues to be carried out by only prescribers trained in insulin therapy’ this will enable prescribers sufficiently trained to prescribe it, and avoid unnecessary restrictions. 2)NICE Technical Appraisals March and April 2018 Technical Appraisals NICE TA indication RAG rating NICE TA504 Pirfenidone for treating idiopathic pulmonary fibrosis RED NICE Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma. RED NICE : Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C. RED NICE Brodalumab for treating moderate to severe plaque psoriasis RED NICE Tivozanib for treating advanced renal cell carcinoma RED NICE Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer. RED NICE Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. RED
10TH-May-2018-newsletter-final.docx